PCV36 ECONOMIC EVALUATION OF PRIMARY PREVENTION OF CVD EVENTS WITH STATINS IN ITALY  by Bustacchini, S et al.
696 Abstracts
developed to project lifetime costs and beneﬁts of lipid therapy.
Clinical trial data were used to estimate LDL-C reductions for
different treatment strategies. Effect of LDL-C reductions on
CHD event rates was estimated using Framingham equations
and Spanish Instituto Nacional de Estadística data on nonCHD-
related mortality. Direct costs of CHD events in Spain, Spanish
prices for simvastatin, atorvastatin and EZ10 were used to
project lifetime costs. Model was run for a population consist-
ing of all CHD and CHD-equivalent patients started on A10 in
an observational Lipid Lowering Treatment study conducted in
Spain, and not at LDL-C goal after 60 days of treatment.
RESULTS: For these patients N = 54 (mean age 62.5 years,
64.8% male, lipid proﬁle on A10 mean LDL-C 148.7mg/dl, 
TC 225.9mg/dl, HDL 45.9mg/dl), switching to EZ10 co-
administered with S20 compared to atorvastatin titration is pro-
jected to increase the life expectancy from 15.99 to 16.31 years
for CHD patients and from 18.11 to 18.23 years for CHD equiv-
alent patients with a discounted incremental cost per life year
gained of 7,855 EURO for CHD patients and 15,356 for CHD
equivalent patients. CONCLUSION: Switching to EZ10 co-
administered with simvastatin for CHD and CHD equivalent
patients not at goal on atorvastatin is projected to be a cost-
effective alternative to atorvastatin titration.
PCV36
ECONOMIC EVALUATION OF PRIMARY PREVENTION OF CVD
EVENTS WITH STATINS IN ITALY
Bustacchini S1, Ruffo P1, Mantovani LG2
1Pﬁzer Italia srl, Rome, Italy; 2University of Milan, Milan, Italy
OBJECTIVES: Cardiovascular diseases (CVD) are the leading
cause of morbidity and mortality. Treatment with statins has
shown to be effective in controlling cholesterol levels in dyslipi-
demic subjects and in preventing CVD. The objective of this
analysis was the evaluation of the economic impact of the CVD
primary prevention with statins in Italy. METHODS: Alterna-
tives: market mix for statins (low dosages assumed as initial
dosages) marketed in Italy (weighted with the current market
shares) compared with no intervention. Population: sample of
high-risk subjects with an absolute CV risk level ≥ 2% per year,
derived from a population study conducted in the Verona area
in Italy. Perspective: National Health Service (NHS). Technique:
cost-effectiveness analysis, making economic and health projec-
tions in a hypothetical cohort of 1000 subjects in primary pre-
vention; an incremental cost per life year gained (ICER LYG) has
been calculated. Time: 10 years. Costs: drugs and direct medical
costs quantiﬁed in using NHS tariffs expressed in Euro 2003.
Effects: the effects of different statins in controlling cholesterol
levels, as measured with the CURVES study (Jones P et al, 1998)
has been used to model coronary (CHD) morbidity and mortal-
ity from CVD with the Framingham risk equations (Anderson
KM et al, 1990). RESULTS: A primary CVD preventive inter-
vention with statins in a hypothetical cohort of 1000 high-risk
subjects can avoid 70 CHD events and 28 CVD deaths, thus 
projecting 138 LYG. After having considered costs for drugs
(4,789,542€) and savings due to events avoided (319,722€), the
net cost of the intervention is 4,469,820€ with a ICER LYG of
32,458€. CONCLUSIONS: The cost-effectiveness proﬁle of
CVD primary preventive intervention with statins is in the range
of what is considered cost-effective in absolute values by the 
scientiﬁc community.
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OBJECTIVES: To estimate—from the German SHI perspec-
tive—economic consequences of using the low-molecular-weight
heparin enoxaparin subcutaneously (ENOX) instead of intra-
venous unfractionated heparin followed by oral phenprocoumon
(UFH/PPC) for anticoagulation in patients undergoing TEE-
guided early electrocardioversion from nonvalvular atrial ﬁbril-
lation (AF). METHODS: As ENOX is noninferior to UFH/PPC
in preventing deaths and ischemic, embolic, and hemorrhagic
events [Stellbrink C, et al. ACE trial. Circulation 2004], a cost-
minimization analysis (CMA) was performed. The target 
variable “incremental cost for ENOX versus UFH/PPC” was
quantiﬁed using a modelling approach based on decision-tree
technique. The CMA encompassed 28 (26–30) treatment days
with phase I of 5 (3–8) days comprising diagnostics, initiation of
anticoagulation, and cardioversion. Phase II with the remaining
days comprised continued anticoagulation. Resource use was
veriﬁed by a survey in the in- and outpatient sectors. Costs 
were given by SHI expenses and were quantiﬁed by multiplying
utilised resource items by the price or tariff of each item, accord-
ing to German Health Care regulations. RESULTS: In the base-
case analysis, phase I was outpatient based for the majority of
ENOX patients opposed to inpatient treatment for all UFH/PPC
patients, whereas phase II was entirely outpatient based for both
patient groups. There were savings of 579€ per patient with
ENOX (892€) compared to UFH/PPC (1471€). Comprehensive
sensitivity analyses (impact analysis, Monte Carlo simulation)
showed the robustness of the model. Expenses for the inpatient-
based phase I with UFH/PPC had by far the greatest inﬂuence
on the extent of savings obtained. Simultaneous random varia-
tion of all model parameters within their empirically given inter-
vals revealed savings obtained by ENOX in 93% of 10,000
simulated comparisons versus UFH/PPC. CONCLUSIONS: In
TEE-guided early electrocardioversion of nonvalvular AF, anti-
coagulation with ENOX offers SHI in Germany an enormous
saving potential when used instead of UFH/PPC.
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OBJECTIVE: To calculate costs for patients with myocardial
infarction (MI) in common medical practice in Russian Federa-
tion. METHODS: Data on resource use for hospital treatment
of patients with acute myocardial infarction were extracted from
99 medical charts at 3 hospitals at Moscow, Tula and Vladimir.
Data on resource use for out-patient follow-up for patients after
acute myocardial infarction were identiﬁed according to experts’
opinion. A total of 12 experts ﬁlled in the questionnaire for iden-
tifying typical follow-up strategy for 1.5 years after MI. Direct
medical costs were calculated on the basis of price-lists for
medical services and median prices for drugs given in a whole-
sale pharmaceutical informational bulletin. RESULTS: Median
